Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (591-600 of 993) with videos related to

Pageof 100
Sort By:
Urologic Oncology|October 23, 2021
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinomaRocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
Minerva Urology and Nephrology|April 23, 2021
Improving the stratification of intermediate risk prostate cancerLuigi Nocera, Claudia Collà Ruvolo, Lara F Stolzenbach, et al.
European Urology|March 27, 2007
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millenniumFelix K-H Chun, Alberto Briganti, Andrea Gallina, et al.
Cancer Causes & Control : CCC|September 3, 2021
Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinomaMike Wenzel, Nicolas Siron, Claudia Collà Ruvolo, et al.
Communications Biology|September 8, 2021
CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosisChahat Mehra, Ji-Hyun Chung, Yi He, et al.
The Prostate|November 6, 2022
Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5Andrea Panunzio, Gabriele Sorce, Benedikt Hoeh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White PatientsLara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, et al.
Urologic Oncology|September 20, 2020
Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidatesClaudia Collà Ruvolo, Lara Franziska Stolzenbach, Luigi Nocera, et al.
Pageof 100

Showing results (591-600 of 993) with videos related to

Sort By:
Pageof 100
Urologic Oncology|October 23, 2021
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinomaRocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsGlenn Heller, Robert McCormack, Thian Kheoh, et al.
Prostate Cancer and Prostatic Diseases|May 31, 2021
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysisMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
Minerva Urology and Nephrology|April 23, 2021
Improving the stratification of intermediate risk prostate cancerLuigi Nocera, Claudia Collà Ruvolo, Lara F Stolzenbach, et al.
European Urology|March 27, 2007
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millenniumFelix K-H Chun, Alberto Briganti, Andrea Gallina, et al.
Cancer Causes & Control : CCC|September 3, 2021
Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinomaMike Wenzel, Nicolas Siron, Claudia Collà Ruvolo, et al.
Communications Biology|September 8, 2021
CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosisChahat Mehra, Ji-Hyun Chung, Yi He, et al.
The Prostate|November 6, 2022
Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5Andrea Panunzio, Gabriele Sorce, Benedikt Hoeh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White PatientsLara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, et al.
Urologic Oncology|September 20, 2020
Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidatesClaudia Collà Ruvolo, Lara Franziska Stolzenbach, Luigi Nocera, et al.
Pageof 100